Vicapsys Life Sciences, Inc. Share Price
Equities
VICP
US92560A1060
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9799 USD | +58.05% | +58.05% | -64.24% |
Sales 2021 | - | Sales 2022 | - | Capitalization | 31.19M 2.49B |
---|---|---|---|---|---|
Net income 2021 | - 0 | Net income 2022 | - 0 | EV / Sales 2021 | - |
Net cash position 2021 | 217K 17.32M | Net cash position 2022 | 14.1K 1.12M | EV / Sales 2022 | - |
P/E ratio 2021 |
-149
x | P/E ratio 2022 |
-30.9
x | Employees | 2 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 43.18% |
1 day | +58.05% | ||
1 week | +58.05% | ||
Current month | -49.75% | ||
1 month | -49.75% | ||
3 months | -21.61% | ||
6 months | -64.37% | ||
Current year | -64.24% |
Managers | Title | Age | Since |
---|---|---|---|
Federico Pier
CEO | Chief Executive Officer | 56 | 30/06/09 |
Jeffery Wright
DFI | Director of Finance/CFO | 41 | 31/05/19 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 65 | 21/09/22 | |
Federico Pier
CEO | Chief Executive Officer | 56 | 30/06/09 |
Charles Farrahar
BRD | Director/Board Member | 63 | 21/09/22 |
1st Jan change | Capi. | |
---|---|---|
-64.24% | 31.43M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- VICP Stock